Millennium Management’s CRISPR Therapeutics CRSP Stock Holding History

Millennium Management’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-33,000	Closed	-$1.55M	–	6030
2024 Q3	$1.55M	Buy	+33,000	New	+$1.67M	﹤0.01%	3932
2024 Q2	–	Sell	-3,100	Closed	-$211K	–	5980
2024 Q1	$211K	Buy	+3,100	New	+$222K	﹤0.01%	5346
2023 Q3	–	Sell	-50,500	Closed	-$2.84M	–	6187
2023 Q2	$2.84M	Buy	50,500 +20,500	+68%	+$1.16M	﹤0.01%	3180
2023 Q1	$1.36M	Buy	+30,000	New	+$1.46M	﹤0.01%	3803
2022 Q3	–	Sell	-20,000	Closed	-$1.22M	–	7125
2022 Q2	$1.22M	Sell	20,000 -1,400	-7%	-$82.3K	﹤0.01%	4201
2022 Q1	$1.34M	Sell	21,400 -6,100	-22%	-$383K	﹤0.01%	4248
2021 Q4	$2.08M	Sell	27,500 -2,500	-8%	-$218K	﹤0.01%	3743
2021 Q3	$3.36M	Buy	30,000 +5,100	+20%	+$641K	﹤0.01%	3333
2021 Q2	$4.03M	Buy	24,900 +2,400	+11%	+$292K	﹤0.01%	3046
2021 Q1	$2.74M	Sell	22,500 -17,500	-44%	-$2.64M	﹤0.01%	3224
2020 Q4	$6.12M	Buy	+40,000	New	+$4.73M	﹤0.01%	2245
2020 Q3	–	Sell	-25,000	Closed	-$1.84M	–	4503
2020 Q2	$1.84M	Buy	+25,000	New	+$1.46M	﹤0.01%	2600

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GSK plc London $599M AUM

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Millennium Management's CRSP Position: Q1 2026 in Review

Millennium Management increased its CRISPR Therapeutics (CRSP) stake by 1,137% in Q1 2026, buying an estimated $18.3M and bringing the position to 377,178 shares worth $17.9M. The position accounts for 0.01% of the portfolio, ranked #1644.

Millennium Management first reported a position in CRSP in Q4 2016 and has held it in 29 quarters since. The position peaked at $29.2M in Q4 2021. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

Millennium Management held 377,178 shares of CRISPR Therapeutics worth $17.9M as of Q1 2026.
Millennium Management bought 346,686 CRISPR Therapeutics shares in Q1 2026, an estimated $18.3M.
CRISPR Therapeutics made up 0.01% of Millennium Management's portfolio in Q1 2026, its #1644 holding.
Millennium Management first reported a position in CRISPR Therapeutics in Q4 2016 and has held it in 29 quarters since.
Millennium Management's CRISPR Therapeutics position peaked at $29.2M in Q4 2021.
488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.